Scpharmaceuticals Inc (NASDAQ:SCPH) — Market Cap & Net Worth
Market Cap & Net Worth: Scpharmaceuticals Inc (SCPH)
Scpharmaceuticals Inc (NASDAQ:SCPH) has a market capitalization of $304.36 Million ($304.36 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14610 globally and #3456 in its home market, demonstrating a 0.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scpharmaceuticals Inc's stock price $5.67 by its total outstanding shares 53678797 (53.68 Million). Review Scpharmaceuticals Inc (SCPH) total liabilities to assess the company's total debt and financial obligations.
Scpharmaceuticals Inc Market Cap History: 2017 to 2025
Scpharmaceuticals Inc's market capitalization history from 2017 to 2025. Data shows change from $648.98 Million to $304.36 Million (-10.90% CAGR).
Index Memberships
Scpharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.01% | #399 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1434 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.02% | #207 of 263 |
Weight: Scpharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Scpharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scpharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.23x
Scpharmaceuticals Inc's market cap is 5.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $384.88 Million | $2.06 Million | -$36.84 Million | 186.56x | N/A |
| 2023 | $336.57 Million | $13.59 Million | -$54.81 Million | 24.76x | N/A |
| 2024 | $190.02 Million | $36.33 Million | -$85.15 Million | 5.23x | N/A |
Competitor Companies of SCPH by Market Capitalization
Companies near Scpharmaceuticals Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Scpharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Scpharmaceuticals Inc Historical Marketcap From 2017 to 2025
Between 2017 and today, Scpharmaceuticals Inc's market cap moved from $648.98 Million to $ 304.36 Million, with a yearly change of -10.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $304.36 Million | +60.17% |
| 2024 | $190.02 Million | -43.54% |
| 2023 | $336.57 Million | -12.55% |
| 2022 | $384.88 Million | +42.83% |
| 2021 | $269.47 Million | -5.10% |
| 2020 | $283.96 Million | -6.54% |
| 2019 | $303.82 Million | +50.53% |
| 2018 | $201.83 Million | -68.90% |
| 2017 | $648.98 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Scpharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $304.36 Million USD |
| MoneyControl | $304.36 Million USD |
| MarketWatch | $304.36 Million USD |
| marketcap.company | $304.36 Million USD |
| Reuters | $304.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scpharmaceuticals Inc
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and … Read more